-
Je něco špatně v tomto záznamu ?
Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
K. Tripska, IC. Igreja Sá, M. Vasinova, M. Vicen, R. Havelek, S. Eissazadeh, Z. Svobodova, B. Vitverova, C. Theuer, C. Bernabeu, P. Nachtigal
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Free Medical Journals od 2014
PubMed Central od 2014
Europe PubMed Central od 2014
Open Access Digital Library od 2014-01-01
Open Access Digital Library od 2014-01-01
ROAD: Directory of Open Access Scholarly Resources od 2014
Odkazy
PubMed
36160139
DOI
10.3389/fmed.2022.845918
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Endoglin (Eng) is a co-receptor of the transforming growth factor β superfamily playing an important role in endothelial dysfunction. TRC105 (carotuximab) is a monoclonal antibody that blocks Eng and its downstream Smad signaling pathway. Here we have investigated for the first time the effects of TRC105 treatment on the development of endothelial dysfunction induced by 7-ketocholesterol (7K) or high glucose (HG), focusing on Eng expression, signaling, and function. In the hypercholesterolemia study, human aortic endothelial cells (HAoECs) were treated with TRC105 (300 μg/ml) for 1 h, followed by the addition of 7K (10 μg/ml) for another 12 h. In the hyperglycemia study, HAoECs were exposed to HG (45 mM) for 60 h, followed by the addition of TRC105 for another 12 h, and cells treated with 5mM glucose and 40 mM mannitol served as control. Protein levels, adhesion, and transmigration of monocytes were assessed by flow cytometry, mRNA expression was measured by qRT-PCR. 7K and HG treatment increased protein levels of NF-κB and Eng and adhesion and transmigration of monocytes through HAoECs monolayer. TRC105 pretreatment reduced the 7K- or HG-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling. Despite increased protein levels of P-selectin and VCAM-1, TRC105 mediated blockage of Eng prevented 7K- and HG-induced adhesion and transmigration of monocytes through endothelial monolayers. These results suggest that TRC105-mediated Eng blockage can counteract the hypercholesterolemia- and hyperglycemia-induced endothelial dysfunction in HAoECs, suggesting that Eng might be a potential therapeutic target in disorders associated with elevated cholesterol and glucose levels.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22023350
- 003
- CZ-PrNML
- 005
- 20221031095201.0
- 007
- ta
- 008
- 221010s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fmed.2022.845918 $2 doi
- 035 __
- $a (PubMed)36160139
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Tripska, Katarina $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
- 245 10
- $a Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells / $c K. Tripska, IC. Igreja Sá, M. Vasinova, M. Vicen, R. Havelek, S. Eissazadeh, Z. Svobodova, B. Vitverova, C. Theuer, C. Bernabeu, P. Nachtigal
- 520 9_
- $a Endoglin (Eng) is a co-receptor of the transforming growth factor β superfamily playing an important role in endothelial dysfunction. TRC105 (carotuximab) is a monoclonal antibody that blocks Eng and its downstream Smad signaling pathway. Here we have investigated for the first time the effects of TRC105 treatment on the development of endothelial dysfunction induced by 7-ketocholesterol (7K) or high glucose (HG), focusing on Eng expression, signaling, and function. In the hypercholesterolemia study, human aortic endothelial cells (HAoECs) were treated with TRC105 (300 μg/ml) for 1 h, followed by the addition of 7K (10 μg/ml) for another 12 h. In the hyperglycemia study, HAoECs were exposed to HG (45 mM) for 60 h, followed by the addition of TRC105 for another 12 h, and cells treated with 5mM glucose and 40 mM mannitol served as control. Protein levels, adhesion, and transmigration of monocytes were assessed by flow cytometry, mRNA expression was measured by qRT-PCR. 7K and HG treatment increased protein levels of NF-κB and Eng and adhesion and transmigration of monocytes through HAoECs monolayer. TRC105 pretreatment reduced the 7K- or HG-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling. Despite increased protein levels of P-selectin and VCAM-1, TRC105 mediated blockage of Eng prevented 7K- and HG-induced adhesion and transmigration of monocytes through endothelial monolayers. These results suggest that TRC105-mediated Eng blockage can counteract the hypercholesterolemia- and hyperglycemia-induced endothelial dysfunction in HAoECs, suggesting that Eng might be a potential therapeutic target in disorders associated with elevated cholesterol and glucose levels.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Igreja Sá, Ivone Cristina $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
- 700 1_
- $a Vasinova, Martina $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
- 700 1_
- $a Vicen, Matej $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
- 700 1_
- $a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
- 700 1_
- $a Eissazadeh, Samira $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
- 700 1_
- $a Svobodova, Zuzana $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
- 700 1_
- $a Vitverova, Barbora $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
- 700 1_
- $a Theuer, Charles $u Tracon Pharmaceuticals, Inc., San Diego, CA, United States
- 700 1_
- $a Bernabeu, Carmelo $u Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Madrid, Spain
- 700 1_
- $a Nachtigal, Petr $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
- 773 0_
- $w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 9, č. - (2022), s. 845918
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36160139 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20221010 $b ABA008
- 991 __
- $a 20221031095159 $b ABA008
- 999 __
- $a ind $b bmc $g 1853825 $s 1174638
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 9 $c - $d 845918 $e 20220907 $i 2296-858X $m Frontiers in medicine $n Front. med. $x MED00188756
- LZP __
- $a Pubmed-20221010